| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
11,447,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
23,616 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.008 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of medicines that benefit patients with medical needs. Co. has two compounds in development, Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients with Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Truex Paul F |
President and CEO |
• – – |
2014-12-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,500 |
0 |
|
- |
|
| Odink Debra |
Chief Technology Officer |
• – – |
2014-12-30 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,364 |
13,855 |
|
- |
|
| Odink Debra |
Chief Technology Officer |
• – – |
2014-12-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,364 |
9,101 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-06-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(14,709) |
14,709 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-06-30 |
4 |
GD |
$0.00 |
$0 |
I/I |
16,500 |
62,128 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-06-30 |
4 |
D |
$3.39 |
$2,370 |
D/D |
(699) |
14,709 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-06-30 |
4 |
OE |
$2.08 |
$4,160 |
D/D |
2,000 |
13,845 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-03-25 |
4/A |
D |
$3.30 |
$29,614 |
D/D |
(8,974) |
11,845 |
|
- |
|
| Odink Debra |
Chief Technology Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,864 |
10,465 |
|
- |
|
| Odink Debra |
Chief Technology Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,864 |
10,465 |
|
- |
|
| Odink Debra |
Chief Technology Officer |
• – – |
2014-03-25 |
4 |
D |
$3.30 |
$9,184 |
D/D |
(2,783) |
6,601 |
|
- |
|
| Odink Debra |
Chief Technology Officer |
• – – |
2014-03-25 |
4 |
D |
$3.30 |
$9,184 |
D/D |
(2,783) |
6,601 |
|
- |
|
| Liu May |
Chief Accounting Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,625 |
7,302 |
|
- |
|
| Liu May |
Chief Accounting Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,625 |
7,302 |
|
- |
|
| Liu May |
Chief Accounting Officer |
• – – |
2014-03-25 |
4 |
D |
$3.30 |
$1,746 |
D/D |
(529) |
3,677 |
|
- |
|
| Liu May |
Chief Accounting Officer |
• – – |
2014-03-25 |
4 |
D |
$3.30 |
$1,746 |
D/D |
(529) |
3,677 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,864 |
24,147 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,864 |
24,147 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2014-03-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,323) |
20,283 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2014-03-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,323) |
20,283 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-03-25 |
4 |
A |
$3.30 |
$20,625 |
I/I |
6,250 |
597,787 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-03-25 |
4 |
A |
$3.30 |
$20,625 |
I/I |
6,250 |
597,787 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,864 |
13,197 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,864 |
13,197 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-03-25 |
4 |
D |
$3.30 |
$25,153 |
D/D |
(7,622) |
9,333 |
|
- |
|
221 Records found
|
|
Page 2 of 9 |
|
|
